Get the app
US › Healthcare

Adlai Nortye Ltd. American Depositary Shares (ANL)

US · Healthcare · Biotechnology

$11.03-8.77%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$7.3M
Revenue YoY
+885.2%
Net profit
$-2.7M
EPS estimate
$-0.35
Net margin
-36.3%

Key statistics

Market cap
$757.0M
Forward P/E
0.0
P/B
4.71
Book value
$3.34
EPS (TTM)
$-0.55
52-week high
$17.25
52-week low
$0.88
50-day MA
$14.55
200-day MA
$10.74
Beta
1.11

Analyst view

Analysts rate Adlai Nortye Ltd. American Depositary Shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $29.50.

Shareholding

Insiders
0.94%
Institutions
41.33%

Largest institutional holders

FundStake
Cormorant Asset Management, LLC6.18%
VR Adviser, LLC4.99%
Balyasny Asset Management LLC4.75%
Point72 Asset Management, L.P.3.32%
MPM Oncology Impact Management LP3.01%
Perceptive Advisors LLC2.78%
Casdin Capital, LLC1.94%
ADAR1 Capital Management LLC1.58%

Recent filings & reports

DocumentDate
Report of foreign private issuer (6-K) · Q3 2026
OTHER NOTABLE POINTS • On September 30, 2026, Adlai Nortye Group Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission. • The compa
2026-09-30
Report of foreign private issuer (6-K) · Q3 2026
HEADLINE NUMBERS • Adlai Nortye Group Ltd. held an Extraordinary General Meeting (EGM) on September 30, 2026. • 40,433,365 ordinary shares were repr
2026-09-30
Report of foreign private issuer (6-K) · Q3 2026
HEADLINE NUMBERS • On September 8, 2026, Adlai Nortye announced that the first patient had been dosed in Australia in a clinical trial of AN4035. •
2026-09-08
Current report (6-K) · Q3 2026
HEADLINE NUMBERS • Adlai Nortye will hold an Extraordinary General Meeting on September 30, 2026 at 10 a.m. Singapore time in Singapore. • Sharehold
2026-08-26
Report of foreign private issuer (6-K) · Q3 2026
HEADLINE NUMBERS • The document is the constitution of Adlai Nortye Group Ltd., registered in Singapore on July 29, 2026, under registration number 2
2026-08-19
Quarterly results (6-K) · Q2 2026
HEADLINE NUMBERS • Revenue was US$13.1 million in 1H26, versus nil in 1H25. All revenue came from the AN9025 exclusive license agreement with Jiangsu
2026-08-14
Annual report FY2025 (20-F)
HEADLINE NUMBERS • Adlai Nortye Ltd. filed its Form 20-F for the fiscal year ended December 31, 2025. • The company had 120,000,803 ordinary shares
2026-04-10
Annual report FY2024 (20-F)2025-04-30

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adlai Nortye Ltd. American Depositary Shares — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.